Status:
RECRUITING
EUS Guided HVA and PVA for Circulating Tumor DNA in Patients
Lead Sponsor:
Chinese University of Hong Kong
Conditions:
Circulating Tumor Cell
Gastrointestinal Cancer
Eligibility:
All Genders
Phase:
NA
Brief Summary
The discovery of cell-free circulating tumor DNA (crDNA) in blood and the maturation of technologies for ctDNA analysis have presented an attractive opportunity for minimally invasive "liquid biopsy" ...
Detailed Description
The discovery of cell-free circulating tumor DNA (crDNA) in blood and the maturation of technologies for ctDNA analysis have presented an attractive opportunity for minimally invasive "liquid biopsy" ...
Eligibility Criteria
Inclusion
- Inclusion criteria:
- Age \>= 18 years old
- Newly diagnosed stage II-IV distal gastric cancer, pancreatic cancer or colorectal cancer
- Undergoing treatment with either:
- Surgery
- Neoadjuvant chemotherapy
- Neoadjuvant chemoirradiation
- Palliative chemotherapy/ immunotherapy
- Exclusion criteria:
- <!-- -->
- Synchronous cancer of other sites
- Cardia, high lesser curve tumors, oesophagogastric junction tumors
- Presence of bulky lymph nodes at lesser curve/ coeliac region precluding a clear EUS puncture site to portal vein and hepatic vein
- Patients with coagulopathy (international normalized ratio \>1.3, partial thromboplastin time greater than twice that of control), platelet count \<50,000x103/uL
- Patients unwilling to undergo follow-up assessments
- Patients with liver cirrhosis, portal hypertension and/ or gastric varices
- Patient refusal to participate
- \-
Exclusion
Key Trial Info
Start Date :
January 1 2021
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 31 2026
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT04782557
Start Date
January 1 2021
End Date
December 31 2026
Last Update
March 4 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
The Chinese University of Hong Kong
Hong Kong, Hong Kong